Status:
RECRUITING
Autoimmunity After Checkpoint Blockade
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Autoimmunity
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the ...
Detailed Description
The goal of this study is to understand how the treatment of cancer with checkpoint inhibitors leads to the development of autoimmunity. Specifically, to understand the genetics and immune system feat...
Eligibility Criteria
Inclusion
- A diagnosis of cancer and prescription for a checkpoint inhibitor
Exclusion
- Any subjects not willing or able to give consent
- Children under the age of 18
- A history of transplant
Key Trial Info
Start Date :
February 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04119713
Start Date
February 24 2020
End Date
June 30 2026
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104